Open AccessPeriodic Mesoporous Organosilica Coated Prussian Blue for MR/PA Dual‐Modal Imaging‐Guided Photothermal‐Chemotherapy of Triple Negative Breast Cancer
Author(s) -
Tian Wei,
Su Yunyan,
Tian Ying,
Wang Shouju,
Su Xiaodan,
Liu Ying,
Zhang Yunlei,
Tang Yuxia,
Ni Qianqian,
Liu Wenfei,
Dang Meng,
Wang Chunyan,
Zhang Junjie,
Teng Zhaogang,
Lu Guangming
Publication year - 2017
Publication title -
advanced science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.388
H-Index - 100
ISSN - 2198-3844
DOI - 10.1002/advs.201600356
Subject(s) - photothermal therapy , prussian blue , triple negative breast cancer , materials science , magnetic resonance imaging , chemotherapy , mesoporous organosilica , breast cancer , cancer , cancer research , mesoporous material , biomedical engineering , mesoporous silica , nanotechnology , medicine , chemistry , radiology , biochemistry , electrode , electrochemistry , catalysis
Complete eradication of highly aggressive triple negative breast cancer (TNBC) remains a notable challenge today. In this work, an imaging‐guided photothermal‐chemotherapy strategy for TNBC is developed for the first time based on a periodic mesoporous organosilica (PMO) coated Prussian blue (PB@PMO) nanoplatform. The PB@PMOs have organic‐inorganic hybrid frameworks, uniform diameter (125 nm), high surface area (866 m 2 g −1 ), large pore size (3.2 nm), excellent photothermal conversion capability, high drug loading capacity (260 µg mg −1 ), and magnetic resonance (MR) and photoacoustic (PA) imaging abilities. The MR and PA properties of the PB@PMOs are helpful for imaging the tumor and showing the accumulation of the nanoplatform in the tumor region. The bioluminescence intensity and tumor volume of the MDA‐MB‐231‐Luc tumor‐bearing mouse model demonstrate that TNBC can be effectively inhibited by the combined photothermal‐chemotherapy than monotherapy strategy. Histopathological analysis further reveals that the combination therapy results in most extensive apoptotic and necrotic cells in the tumor without inducing obvious side effect to major organs.